A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., May 17, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., May 11, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo...
Aggressive go-to-market sales, partnerships, and marketing strategy to bring INVOcell, fertility care that is accessible, inclusive, and affordable to the more than 90% of couples in need of fertility treatment that currently go without care.SARASOTA, Fla., May 10,...
Current Senior Advisor at McKinsey & Co. with strong expertise in global marketing and brand buildingSARASOTA, Fla., April 26, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo...
- RESOLVE is a non-profit action-based, infertility and family building organization who want to see increased access to all family building options- It's estimated that nearly 90% of couples in need of infertility treatment go without careSARASOTA, Fla., April 22,...
- Approximately one in eight couples are affected by infertility in the United StatesSARASOTA, Fla. and SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo...
SARASOTA, Fla., April 12, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
Company to Host Conference Call on March 30 at 4:30pm ET (Details Below)SARASOTA, Fla., March 30, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
SARASOTA, Fla., March 29, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., March 26, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo...
INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solutionClinic to be located in Birmingham, Alabama with a focus on providing INVOcell as an efficient, effective and affordable fertility treatment option for the...
SARASOTA, Fla., March 11, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...
SARASOTA, Fla., March 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...
SARASOTA, Fla., March 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...
- Spain marks INVO's initial entry into the European market- Europe represents approximately 30% of the multi-billion dollar global fertility marketplace- The first three clinics in Spain have placed initial orders for INVOcell - an effective and affordable...
- Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan- Seeks to expand access to infertility care in the fifth most populous country in the world, Pakistan, with approximately 212 million...
Key Developments and Future Initiatives Position INVOcell® Within the Severely Underserved Fertility MarketSARASOTA, Fla., Jan. 7, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ('INVO"), a medical device company focused on commercializing...
- Malaysia represents a significant addressable market opportunity with approximately 10% of the population suffering from infertility.- idsMED is one of the largest and most well-respected medical solutions providers in the region.- Product registration is already...
SARASOTA, Fla., Nov. 18, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the formation of its Scientific Advisory Board (SAB) with the appointment of several...
Company to Provide Investor Update on November 19 at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with...
Joint Venture Targets the Large and Growing Mexico Market for Infertility ServicesSARASOTA, Fla., Sept. 30, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today it...
INVO's Board strengthened with independent directors as we enter a new growth trajectory for the CompanySARASOTA, Fla., Sept. 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients...
Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1x1 MeetingsSARASOTA, Fla., Aug. 13, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company...
SARASOTA, Fla., Aug. 6, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in...
- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving- "As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility...
- According to AIRM, "IVF with INVOcell is a simple, cost-effective, and highly rewarding methodology to increase access to care for assisted reproduction"- Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are...
SARASOTA, Fla., June 29, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
SARASOTA, Fla., June 23, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo...
Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treatedSARASOTA, Fla., June 19, 2020 /PRNewswire/ -- Today, Steve Shum, Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB:...
SARASOTA, Fla., May 22, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
Company to Participate in Virtual Investor Conference on May 20 at 2:00pm ET (Details Below)SARASOTA, Fla., May 15, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed...
SARASOTA, Fla., April 2, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, announced today the appointment of Christopher A. Myer as Vice President Business...
SARASOTA, Fla., March 30, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
INVO's novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility marketSARASOTA, Fla., March 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO)...